PaulStevenYamauchiMDPhD

Cosmetic Dermatology, Dermatologic Surgery

Medical Director Dermatology Institute and Skin Care Center Medical Director Clinical Science Institute Clinical Assistant Professor David Geffen School of Medicine at UCLA Adjunct Associate Professor John Wayne Cancer Center

Join to view full profile

Dr. Yamauchi is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Yamauchi's full profile

Already have an account?

Office
2001 Santa Monica Blvd
Ste 1160W
Santa Monica, CA 90404
Phone+1 310-829-4104

Fax+1 310-829-4150

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Dermatology, 1997 - 2000
University of RochesterResidency, Orthopaedic Surgery, 1992 - 1994
University of Rochester Medical CenterInternship, Transitional Year, 1991 - 1992
Case Western Reserve University School of MedicineClass of 1991

Certifications & Licensure

CA State Medical License 1994 - 2026
American Board of Dermatology Dermatology

Awards, Honors, & Recognition

America's Top Doctors Castle Connolly
Marquis Who's Who in America
Marquis Who's Who in Medicine and Healthcare
Super Doctor SuperDoctors.com
Fellow (FAAD) American Academy of Dermatology
Fellow (FASDS) American Society for Dermatologic Surgery
Join now to see all

Clinical Trials

Efficacy and Safety of Fixed Combination Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel in the Treatment of Acne Vulgaris Start of enrollment: 2007 Feb 01
Completed
Phase 3
A Study to Evaluate the Effectiveness of STELARA ™ (USTEKINUMAB) in the Treatment of Scalp Psoriasis Start of enrollment: 2012 Aug 01
Unknown status
Phase 4
Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO) Start of enrollment: 2014 Jun 16
Completed
Phase 3
A Study of the Efficacy and Safety of DFD-06 Cream in the Treatment of Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Dec 01
Completed
Phase 3
A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis Start of enrollment: 2015 Aug 01
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Genital Psoriasis Start of enrollment: 2016 Apr 01
Completed
Phase 3
A Dose-Ranging Phase II Study of AUR101 in Psoriasis (INDUS-3) Start of enrollment: 2021 May 04
Completed
Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

Efficacy and safety of the ustekinumab biosimilar ABP 654 in patients with moderate-to-severe plaque psoriasis: a randomized, double-blinded, active-controlled, compar...
Andrew Blauvelt, Kim Papp, Mona Trivedi, Carolina Barragan, Vincent Chow
The British Journal of Dermatology. 2024-10-23
Full Guidelines-From the Medical Board of the National Psoriasis Foundation: Perioperative management of systemic immunomodulatory agents in patients with psoriasis an...
Warren A James, Angela L Rosenberg, Jashin J Wu, Sylvia Hsu, April Armstrong
Journal of the American Academy of Dermatology. 2024-08-01
1 citations
Efficacy and safety of tildrakizumab for the treatment of moderate-to-severe plaque psoriasis of the scalp: A multicenter, randomized, double-blind, placebo-controlled...
Kurt Gebauer, Lynda Spelman, Paul S Yamauchi, Jerry Bagel, Tushar Nishandar
Journal of the American Academy of Dermatology. 2024-07-01

Lectures

Psoriasis and Atopic Dermatitis: Advances in Immunology and Therapy
American Academy of Dermatology - Annual Meeting 2019 - Washington, D.C. - 3/2/2019